OTCPK:NNCS.F

Stock Analysis Report

Executive Summary

Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies.

Snowflake

Fundamentals

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has Nanosonics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.7%

NNCS.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

93.4%

NNCS.F

9.9%

US Medical Equipment

0.7%

US Market

NNCS.F outperformed the Medical Equipment industry which returned 9.9% over the past year.

NNCS.F outperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

NNCS.FIndustryMarket
7 Day0.7%1.1%-0.6%
30 Day28.8%1.3%2.9%
90 Day9.9%3.0%1.3%
1 Year93.4%93.4%10.8%9.9%2.9%0.7%
3 Year60.4%60.4%70.1%64.9%44.6%35.2%
5 Year342.4%342.4%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Nanosonics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Nanosonics undervalued based on future cash flows and its price relative to the stock market?

142.37x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Nanosonics's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Nanosonics's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Nanosonics is overvalued based on earnings compared to the US Medical Equipment industry average.

Nanosonics is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Nanosonics is poor value based on expected growth next year.


Price Based on Value of Assets

Nanosonics is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Nanosonics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

31.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Nanosonics's revenue is expected to grow by 19.3% yearly, however this is not considered high growth (20% yearly).

Nanosonics's earnings are expected to grow significantly at over 20% yearly.

Nanosonics's revenue growth is expected to exceed the United States of America market average.

Nanosonics's earnings growth is expected to exceed the United States of America market average.

Nanosonics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Nanosonics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Nanosonics performed over the past 5 years?

39.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Nanosonics has delivered over 20% year on year earnings growth in the past 5 years.

Nanosonics's 1-year earnings growth exceeds its 5-year average (136.5% vs 39.7%)

Nanosonics's earnings growth has exceeded the US Medical Equipment industry average in the past year (136.5% vs 28.2%).


Return on Equity

Nanosonics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Nanosonics used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Nanosonics has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Nanosonics's financial position?


Financial Position Analysis

Nanosonics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Nanosonics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Nanosonics has no debt.

Nanosonics has no debt compared to 5 years ago when it was 39.6%.

Nanosonics has no debt, it does not need to be covered by operating cash flow.

Nanosonics has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Nanosonics has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Nanosonics's current dividend yield, its reliability and sustainability?

0.035%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Unable to evaluate Nanosonics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Nanosonics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Nanosonics has not reported any payouts.

Unable to verify if Nanosonics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Nanosonics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Nanosonics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Nanosonics's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Michael Kavanagh 0

5.9yrs

Tenure

AU$1,163,884

Compensation

Mr. Michael C. Kavanagh, BSc, MBA (Advanced,) has been the Chief Executive Officer and President of Nanosonics Limited since October 21, 2013 and served as its Managing Director. Mr. Kavanagh served as a S ...


CEO Compensation Analysis

Michael's remuneration is lower than average for companies of similar size in United States of America.

Michael's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.0yrs

Average Tenure

The tenure for the Nanosonics management team is about average.


Board Age and Tenure

5.0yrs

Average Tenure

The tenure for the Nanosonics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellAU$19,972,65506 May 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares5,738,122
Max PriceAU$3.48
BuyAU$9,405,37406 May 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares2,776,810
Max PriceAU$3.39
SellAU$128,90930 Apr 19
David Fisher
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares40,000
Max PriceAU$3.22
BuyAU$306,95023 Apr 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares96,178
Max PriceAU$3.20
BuyAU$455,06823 Apr 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares153,745
Max PriceAU$2.96
SellAU$531,09223 Apr 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares195,122
Max PriceAU$2.72
SellAU$3,683,46903 Mar 19
Maurie Stang
EntityIndividual
Role
Chairman of the Board
Non Executive Chairman of the Board
Shares1,250,000
Max PriceAU$2.95
SellAU$928,74926 Feb 19
Michael Kavanagh
EntityIndividual
Role
Chief Executive Officer
CEO, President
Shares310,000
Max PriceAU$3.00
BuyAU$29,380,05301 Feb 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares12,937,627
Max PriceAU$2.33
SellAU$2,670,94923 Nov 18
JCP Investment Partners Limited
EntityCompany
Shares1,287,104
Max PriceAU$2.25
SellAU$16,528,03325 Oct 18
JCP Investment Partners Limited
EntityCompany
Shares6,760,164
Max PriceAU$2.44
BuyAU$8,815,75625 Oct 18
JCP Investment Partners Limited
EntityCompany
Shares3,933,414
Max PriceAU$2.24
SellAU$1,734,44003 Oct 18
JCP Investment Partners Limited
EntityCompany
Shares669,800
Max PriceAU$2.62
BuyAU$2,558,79327 Sep 18
JCP Investment Partners Limited
EntityCompany
Shares1,133,914
Max PriceAU$2.26

Ownership Breakdown


Management Team

  • Michael Kavanagh

    CEO, President

    • Tenure: 5.9yrs
    • Compensation: AU$1.16m
  • David Morris

    Chief Strategy Officer & Regional President Asia Pacific

    • Tenure: 0.6yrs
    • Compensation: AU$274.55k
  • Keith Koby

    Senior Vice President of Sales - North America

    • Tenure: 2.9yrs
  • McGregor Grant

    CFO & Company Secretary

    • Tenure: 8.4yrs
    • Compensation: AU$567.33k
  • Vincent Wang

    Head of Global Customer Support & Technical Services

    • Tenure: 0yrs
    • Compensation: AU$202.22k
  • Leanne Baxendale

    Head of People & Culture

    • Tenure: 2.5yrs
  • Steven Farrugia

    Chief Technology Officer

    • Tenure: 1.6yrs
    • Compensation: AU$515.34k
  • Ken Shaw

    Regional President of United States

    • Tenure: 2yrs
    • Compensation: AU$659.22k
  • Renee Salaberry

    Chief Marketing Officer

    • Tenure: 0.7yrs
  • Rod Lopez

    Chief Operating Officer

    • Tenure: 0.5yrs
    • Compensation: AU$187.53k

Board Members

  • Steve Sargent (59yo)

    Non-Executive Deputy Chairman of the Board & Lead Independent Director

    • Tenure: 1.9yrs
    • Compensation: AU$100.00k
  • Michael Kavanagh

    CEO, President

    • Tenure: 5.9yrs
    • Compensation: AU$1.16m
  • Maurie Stang

    Non Executive Chairman of the Board

    • Tenure: 12.5yrs
    • Compensation: AU$170.00k
  • David Fisher

    Non-Executive Director

    • Tenure: 18.2yrs
    • Compensation: AU$100.00k
  • Geoff Wilson

    Non-Executive Director

    • Tenure: 0.2yrs
  • Marie McDonald (63yo)

    Non-Executive Director

    • Tenure: 2.9yrs
    • Compensation: AU$85.00k
  • Ronan Wright

    Regional President of Europe

    • Tenure: 0yrs

Company Information

Nanosonics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nanosonics Limited
  • Ticker: NNCS.F
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$1.940b
  • Listing Market Cap: AU$1.313b
  • Shares outstanding: 300.31m
  • Website: https://www.nanosonics.com.au

Number of Employees


Location

  • Nanosonics Limited
  • 14 Mars Road
  • Lane Cove
  • New South Wales
  • 2066
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NANASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMay 2007
OQSDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2007
NNCS.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2007
NANCHIA (Chi-X Australia)YesOrdinary SharesAUAUDMay 2007

Biography

Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company manuf ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:43
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.